Meta-analysis · people
Abaloparatide: larger hip BMD gains than teriparatide at 24 weeks
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
In pooled trials of postmenopausal women, abaloparatide gave somewhat larger hip bone density gains than teriparatide with less hypercalcemia, but whether that means fewer fractures was not settled.
- Kind
- Meta-analysis
- Studied in
- People
- Published
- 2023
- Journal
- J Orthop Surg Res
What they tested
The team asked whether abaloparatide raises bone mineral density more than teriparatide in postmenopausal women with osteoporosis, and how the two compare on side effects.
How the study was done
A meta-analysis, which pools results from several studies, covering 16 subgroups of postmenopausal women with osteoporosis. It drew on randomized controlled trials and post hoc analyses of them, published up to September 2, 2022, and compared abaloparatide with teriparatide and with placebo, a dummy treatment.

Model. Individual results vary.
What they found
At 24 weeks, every bone mineral density (BMD) measure except the lumbar spine favored abaloparatide over teriparatide. Only the femoral neck and total hip results reached high quality on the GRADE scale, a rating of how trustworthy the evidence is: weighted mean difference 1.58 [0.52, 2.63] at the femoral neck and 1.46 [0.59, 2.32] at the total hip. Serious side effects and deaths showed no clear difference between the drugs, and hypercalcemia, too much calcium in the blood, was 51% less common with abaloparatide than with teriparatide. Compared with placebo, abaloparatide carried higher risks of nausea and palpitations.
What it doesn’t show
The pool of studies was small, and every head-to-head trial was sponsored by the manufacturer. The fracture data were too limited to judge whether either drug prevents more fractures.
The paper
Hong et al. Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis. J Orthop Surg Res. 2023.
The compounds
More studies on Abaloparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Abaloparatide raised hip BMD around a virtual hip stem in ACTIVERandomized trial · people · 2024
- Abaloparatide improved hip geometry vs placebo in ACTIVE-JRandomized trial · people · 2023
- Abaloparatide then alendronate: 84% lower vertebral fracture riskRandomized trial · people · 2018
- Abaloparatide: normal bone biopsies after up to 18 months in ACTIVERandomized trial · people · 2017
- Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVERandomized trial · people · 2016
- Every study on Abaloparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.